このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Oryzon Genomics マネジメント

マネジメント基準チェック /24

Oryzon Genomics'の CEO はCarlos Manuel Arjolで、 Jan2000年に任命され、の在任期間は 24.42年です。は、会社の株式の5.04%を直接所有しており、その価値は€ 5.47M 。経営陣と取締役会の平均在任期間はそれぞれ3.7年と8.6年です。

主要情報

Carlos Manuel Arjol

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	24.5yrs
CEOの所有権	5.0%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	8.7yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Carlos Manuel Arjol

24.5yrs

在職期間

US$62,992

報酬

Dr. Carlos Manuel Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Carlos Manuel Arjol	Co-Founder	24.5yrs	US$62.99k	5.04% $ 5.2m
Enric Condomines	Director of Operations	4.1yrs	データなし	データなし
Jordi Pey	Chief Scientific Officer	3.5yrs	データなし	データなし
Xavier Ribera	Head of Internal Audit & Compliance	no data	データなし	データなし
Emili Cortada	Chief Business Development Officer	no data	データなし	データなし
Neus Bernado	Chief Intellectual Property Officer	12.8yrs	データなし	データなし
Michael Ropacki	Chief Medical Officer of CNS	3.5yrs	データなし	データなし
Sonia Paloma Bezon	Chief of Clinical Operations	6.8yrs	データなし	データなし
Ana Limon	Senior Vice President of Clinical Development & Global Medical Affairs	2.5yrs	データなし	データなし
Douglas Faller	Global Chief Medical Officer	2.3yrs	データなし	データなし
Augusto Rubio	Secretary	no data	データなし	データなし

3.8yrs

平均在職期間

経験豊富な経営陣: 0RDBの経営陣は経験豊富であると考えられます ( 3.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Carlos Manuel Arjol	Co-Founder	23.5yrs	US$62.99k	5.04% $ 5.2m
Howard Fillit	Member of Scientific Advisory Board	no data	データなし	データなし
Isabel Navarro	Independent Director	8.7yrs	US$7.60k	データなし
Lori Kunkel	Member of Scientific Advisory Board	6.4yrs	データなし	データなし
Manuel López-Figueroa	Lead Independent Director	4.2yrs	データなし	データなし
Josep Echarri Torres	Director	22.4yrs	US$6.52k	2.16% $ 2.2m
Tamara Maes	VP of the Board & President of Scientific Advisory Board	24.5yrs	US$62.99k	4.33% $ 4.5m
Ramon Ramon	Independent Director	8.7yrs	US$7.60k	0.032% $ 33.0k
Leon Hooftman	Member of Scientific Advisory Board	no data	データなし	データなし
Antonio Melero	Independent Director	8.7yrs	US$7.60k	データなし
Felipe Cardoso	Member of Scientific Advisory Board	no data	データなし	データなし
Jose Molinuevo	Member of Scientific Advisory Board	no data	データなし	データなし

8.7yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: 0RDBの取締役会は経験豊富であると考えられます ( 8.6年の平均在任期間)。

Oryzon Genomics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Oryzon Genomics S.A. Announces Executive Changes

Recent updates

Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference

Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024

Forecast breakeven date moved forward to 2025

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

New major risk - Revenue and earnings growth

New minor risk - Profitability

Forecast to breakeven in 2025

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

New major risk - Financial position

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

New major risk - Financial position

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

Insufficient new directors

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Forecast to breakeven in 2025

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics S.A. Presents Iadademstat 36-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Announces $1 Million Grant from Kabuki Syndrome Philanthropists to Support A Precision Medicine Phase I/Ii Trial with Vafidemstat

First half 2021 earnings released: €0.019 loss per share (vs €0.026 loss in 1H 2020)

Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML

ORYZON to Present New Clinical Data

Oryzon Genomics, S.A. Announces Successful pre-IND Meeting with FDA for the Clinical Development of vafidemstatin Borderline Personality Disorder

Oryzon Genomics S.A. Presents Vafidemstat 12-Month Clinical Data from Its Phase IIa Clinical Trials

Full year 2020 earnings released

New 90-day high: €3.84

Oryzon Genomics S.A. Launches Pioneering Schizophrenia Precision Medicine Study in Collaboration with Columbia Psychiatry

New 90-day high: €3.18

New 90-day low: €2.69

Oryzon Genomics S.A. to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Oryzon Genomics, S.A. Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. Announces Executive Changes

Third quarter earnings released

New 90-day low: €2.71

Oryzon Genomics S.A. has completed a Follow-on Equity Offering in the amount of €20.00075 million.

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24